On April 11, 2024 LaNova Medicines Ltd. reported the initiation of its first Phase III clinical trial for LM-302 (anti-Claudin 18.2 ADC) in China (Press release, LaNova Medicines, APR 11, 2024, View Source [SID1234655991]). This marks the first antibody-drug conjugate candidate in LaNova’s pipeline to enter the pivotal clinical study.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The clinical study (CTR20240955) is a randomized, open-label, multi-center, positive-controlled Phase III trial primarily assessing the efficacy and safety of LM-302 in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma who are CLDN18.2 positive.